4 June 2020 in Journal of Clinical Pharmacy and Therapeutics
23 July 2023 in JACCP: Journal of the American College of Clinical Pharmacy
1 June 2020 in Drug Metabolism and Drug Interactions
Objectives: Valproic acid (VPA) is an anticonvulsant used in several clinical scenarios. VPA has been increasingly associated with intentional or unintentional overdose. In patients presenting with severe VPA overdose, supportive care and airway protection are cornerstones of treatment, while levocarnitine is suggested in patients with hyperammonemia and hemodialysis is recommended in patients with VPA serum concentrations (SC) >1,300 mg/L and presence of cerebral edema or shock. Meropenem is a carbapenem antibiotic with a broad spectrum of activity. The pharmacological interaction between VPA and meropenem is characterized by a rapid decrease in VPA concentrations, which contraindicates concurrent use. Case presentation: The following case report describes the use of meropenem to enhance the clearance of VPA in the case of severe VPA overdose. A patient with altered mental status was transported to the emergency department (ED) after VPA overdose. Meropenem was prescribed for significant elevated VPA SC. An important decline in SC was observed with short-term meropenem dosing, and an improvement in mental status occurred shortly after administration. Conclusions: Carbapenem therapy has the potential to be used as last line strategy in the management of severe VPA overdose in patients where SC represent a significant risk of toxicity and clinical symptoms suggest difficulty managing the patient.
4 March 2026 in Journal of Antimicrobial Chemotherapy
Continuous infusion (CI) of linezolid has been proposed to stabilize exposure and improve pharmacokinetic/pharmacodynamic (PK/PD) target attainment compared with conventional intermittent dosing. By maintaining concentrations above inhibitory thresholds, CI may optimize antibacterial efficacy and reduce inter- and intra-patient variability. However, this ‘new way of dosing’ revisits ‘old risks’ associated with linezolid, including nonlinear PK, metabolic saturation, and concentration-dependent toxicities such as lactic acidosis, myelosuppression and neurotoxicity. Rather than eliminating these concerns, CI may accentuate them by prolonging exposure near toxic thresholds, particularly in patients with impaired elimination. Current evidence is predominantly PK; robust clinical outcome data remain limited. Our review synthesizes pharmacometric, observational and trial data and outlines how therapeutic drug monitoring and model-informed precision dosing can be used to individualize CI while surveilling for toxicity. We propose a pragmatic framework for candidate selection, regimen design aligned to PK/PD goals, early therapeutic drug monitoring with adaptive adjustments and vigilant safety monitoring. Overall, CI of linezolid is mechanistically attractive but is not established as standard of care; its use should remain individualized, safety-conscious and evidence-generating pending randomized controlled trials.
18 December 2019 in Drug Metabolism and Personalized Therapy
Phenytoin is widely used in neurocritical patients. Owing to its high pharmacokinetic variability and narrow therapeutic range, plasma level-guided dosing has become the standard. Bayesian prediction (BP) is considered the most flexible and precise pharmacokinetic strategy among several options. A retrospective study of BP dosage adjustment in 20 patients (35 plasma measures) was developed. Results indicated that 70% of phenytoin plasma levels of first plasma samples were beyond the therapeutic range. Phenytoin doses were also estimated according to BP for all patients. The measurements confirmed the ability of the strategy to lead to optimal dosage in 80% of patients, thus indicating a three-fold improvement over the basing dosage adjustment recommended in the literature.